Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Stage: Development Stage Company
Operations: NanoViricides is a nano-biopharmaceutical company focused on discovering and developing therapeutics for life-threatening viral infections (including HIV, Hepatitis, Influenza, Rabies, and Ebola). The company holds an exclusive perpetual license from TheraCour Pharma, Inc. for its core technology. As of the reporting date, the company has no commercial products, no customers, and no revenue.
Key Financial Metrics
| Metric | Nine Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2008 | Balance Sheet (Mar 31, 2009) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,162,978) | $(1,745,585) | N/A |
| Accumulated Deficit | N/A | N/A | $(11,370,715) |
| Cash and Cash Equivalents | N/A | N/A | $1,228,056 |
| Total Assets | N/A | N/A | $2,570,766 |
| Total Liabilities | N/A | N/A | $675,654 |
| Operating Expenses | $2,193,362 | $1,793,155 | N/A |
| Net Cash Used in Operating Activities | $(2,252,240) | $(2,205,135) | N/A |
| Net Cash Provided by Financing Activities | $3,377,553 | $2,500,020 | N/A |
Note: The company reported no revenue for the period. Operating expenses increased primarily due to higher Research and Development costs ($1,331,661 vs $809,140 in the prior period).
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended March 31, 2009, increased to $2.16 million from $1.75 million in the prior year period, driven by a $522,521 increase in Research and Development expenses.
- Capital Expenditures: Significant increase in investing cash outflows ($713,643 vs $51,846) due to purchases of property and equipment ($537,417) and trademarks ($176,226).
- Financing Activity: The company raised $3.38 million in net proceeds from the issuance of common stock and warrants during the nine-month period, compared to $2.50 million in the prior year.
- Balance Sheet Growth: Total assets increased from $1.47 million to $2.57 million, largely due to cash inflows from financing and capital asset acquisitions.
Outlook, Risks, and Management Commentary
Liquidity and Capital Resources
Management states that the company has substantial doubt regarding its ability to continue as a going concern. With a cash balance of $1.23 million, the company estimates it can fund operations only through approximately September 30, 2009. The company projects a need for an additional $3 million to $5 million over the next twelve months to advance drug development, cover capital costs, and fund staffing.
Guidance and Plan of Operation
The company plans to prioritize drug development programs (FluCide, RabiCide, EKCCide, HIVCide, Dengue, and Ebola/Marburg) to generate data for an Investigational New Drug (IND) application. Management intends to raise additional capital through equity or debt financing. If funding is not secured, the company may be forced to curtail operations significantly.
Risks and Contingencies
- Going Concern: Significant operating losses and capital requirements raise substantial doubt about the company's ability to continue operations without additional financing.
- Related Party Dependence: The company relies heavily on TheraCour Pharma, Inc. (a related party and major shareholder) for technology licensing, manufacturing, and laboratory supplies. Development costs charged by TheraCour were $1.44 million for the nine-month period.
- Internal Controls: The company previously reported material weaknesses in internal controls regarding the timeliness of financial reporting and segregation of duties. Management claims to have taken steps to remediate these issues.
- Regulatory Risk: All drug candidates are in pre-clinical stages; there is no assurance of FDA approval or commercial success.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "September 30, 2009" cash runway estimate given the high burn rate and potential for unexpected capital costs.
- Related Party Transactions: Review the terms of the license agreement with TheraCour Pharma, Inc., specifically the 15% royalty on net sales and the "Development Fee" structure (costs plus 30%), to assess future liability.
- Financing Progress: Monitor subsequent filings for evidence of the required $3M-$5M capital raise; failure to secure this will likely halt operations.
- Internal Control Remediation: Confirm that the material weaknesses in financial reporting (segregation of duties) have been fully resolved to ensure future financial statement reliability.
- Collaboration Agreements: Verify the status of the Material Transfer Agreement with the unnamed major pharmaceutical company regarding the eye drug candidate and any potential co-development deals.